Cart
sales@molnova.com
ML-211
CAS No. 2205032-89-7
ML-211( —— )
Catalog No. M23993 CAS No. 2205032-89-7
ML-211 is a carbamate-based dual inhibitor of LYPLA1 (IC50 = 17 nM) and the related LYPLA2 (IC50 = 30 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 272 | In Stock |
|
| 10MG | 408 | In Stock |
|
| 25MG | 672 | In Stock |
|
| 50MG | 945 | In Stock |
|
| 100MG | 1278 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameML-211
-
NoteResearch use only, not for human use.
-
Brief DescriptionML-211 is a carbamate-based dual inhibitor of LYPLA1 (IC50 = 17 nM) and the related LYPLA2 (IC50 = 30 nM).
-
DescriptionML-211 is a carbamate-based dual inhibitor of LYPLA1 (IC50 = 17 nM) and the related LYPLA2 (IC50 = 30 nM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorLYPLA1|LYPLA2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2205032-89-7
-
Formula Weight418.5
-
Molecular FormulaC25H30N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCC(C)(C)C1CCN(CC1)C(=O)N2N=CC(=N2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Adibekian A , Martin B R , Chang J W , et al. Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 2 (LYPLA2)[J]. National Center for Biotechnology Information (US), 2010.
molnova catalog
related products
-
ACTH (1-17) (TFA)
ACTH (1-17) TFA is a corticotrophin analogue and an effective human melanocortin 1 (MC1) receptor agonist with Ki value of 0.21 nM.
-
PRUNETIN-4-GLUCOSIDE
Prunetin 5-O-β-D-glucopyranoside is an isoflavone isolated from extracts of Potentilla astracanica. Prunetin 5-O-β-D-glucopyranoside is a potent and uncompetitive inhibitor of α-glucosidase, with an IC50 of 56.05 μg/mL. Prunetin 5-O-β-D-glucopyranoside can be used for the research of type-2 diabetes.
-
Glembatumumab vedoti...
Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate with potent anticancer effects, utilized in the study of triple negative breast cancer (TNBC).
